US Oncology Named to FORTUNE Magazine's Most Admired Companies List for ... ( HOUSTON March 12 /PRNewswire/ -- ...)

US Oncology Named to FORTUNE Magazine's Most Admired Companies List for Third Time

Date:3/12/2009

HOUSTON, March 12 /PRNewswire/ -- US Oncology, Inc., one of the nation's largest cancer care services companies, has been named to FORTUNE magazine's Most Admired Companies list for 2009. The company ranks third in the Health Care: Pharmacy and Other category. This is the third time US Oncology has been honored with FORTUNE magazine's Most Admired Companies distinction, having been named to the list in 2004 and 2007 in the Diversified Outsourcing Services category.

The magazine's annual list is considered the definitive report card on corporate reputations. Ranked by top industry executives and financial analysts on nine areas of leadership, US Oncology placed third in its sector in the categories of:

Innovation
People management
Use of corporate assets
Social responsibility
Quality of product/services

The company ranks in the top five of all nine categories, including quality of management, financial soundness (ranked 4), long-term investment and global competitiveness (ranked 5).

US Oncology collaborates with providers, payers, biotech/pharmaceutical and medical equipment manufacturers to increase patient access to advanced cancer care. Recent innovation at US Oncology includes:

Innovent Oncology and Level I Pathways: payers and providers working together to give patients the highest quality care possible at more predictable costs. Using evidence-based treatment guidelines, disease man
'/>"/>

0

GOOD

Page: 1 2 3
Related biology technology :

1. Campbell Alliance Brand Management Practice to Present at EyeForPharmas Oncology Summit USA and Oncology Market Access Europe Conference
2. Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
3. Encorium Group Signs $3.1 Million of New Business Contracts Including an Extension of a Current U.S. Oncology Clinical Trial with a Major Pharmaceutical Company
4. Pharmatech 2.0: Introducing Pharmatech Oncology
5. Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting
6. Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug
7. Varian Medical Systems Introducing OncoView(TM) - an Oncology Specific Image Management and Storage Solution
8. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
9. Onyx Pharmaceuticals Licenses Rights to Novel Targeted Oncology Agent From BTG International
10. Radiation Therapy Oncology Group and US Oncology Enter Collaboration to Increase Patient Access to National Clinical Trials
11. First Coast Oncology to Offer Next Generation Proton Therapy

Post Your Comments:

US Oncology Named to FORTUNE Magazine's Most Admired Companies List for ...( HOUSTON March 12 /PRNewswire/ -- ...)